ARTICLE | Finance
GenScript planning to spin out CAR T unit Legend as U.S.-listed company
March 10, 2020 6:23 PM UTC
Updated on Mar 11, 2020 at 12:15 AM UTC
CAR T company Legend Biotech has filed for a U.S. listing as a stand-alone company, parent company GenScript said Tuesday.
In a regulatory filing with Hong Kong Exchanges and Clearing Ltd., GenScript Biotech Corp. (HKSE:1548) proposed that Legend Biotech Corp. be listed separately on a U.S. exchange via a sale of ADSs. Legend, a majority-owned subsidiary of GenScript, houses both allogeneic and autologous CAR T cell therapies...